瑞康医药 (002589.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	7.2B	7.3B	8.0B	8.0B	12.3B
Cost of Revenue	6.5B	6.5B	7.1B	7.2B	10.6B
Gross Profit	751.0M	776.1M	876.4M	827.0M	1.7B
Operating Expenses
R&D Expense	18.7M	20.9M	18.3M	14.6M	22.7M
SG&A Expense	—	—	—	—	—
General & Admin Expense	312.8M	330.7M	397.6M	408.3M	699.9M
Selling & Marketing Expense	300.5M	328.9M	360.5M	432.0M	847.1M
Other Expenses	—	—	—	—	—
Total Operating Expenses	782.5M	833.5M	940.5M	1.0B	2.0B
Cost and Expenses	7.3B	7.4B	8.0B	8.2B	12.6B
Operating Income (EBIT)	12.5M	16.9M	14.6M	(126.6M)	(1.7B)
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	(1.6M)	2.7M	30.6M	(135.4M)	(1.7B)
Income Tax Expense	(44.5M)	(41.2M)	578.0K	(167.4M)	(4.9M)
Bottom Line
Net Income	14.4M	16.1M	12.3M	20.3M	(1.8B)
Earnings from Cont. Ops	42.8M	43.9M	30.1M	32.0M	(1.7B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	14.4M	16.1M	12.3M	20.3M	(1.8B)
Per Share
Basic EPS	CN¥0.01	CN¥0.01	CN¥0.01	CN¥0.01	(CN¥1.24)
Diluted EPS	CN¥0.01	CN¥0.01	CN¥0.01	CN¥0.01	(CN¥1.24)
Revenue Per Share	CN¥4.82	CN¥4.54	CN¥6.48	CN¥5.34	CN¥8.34
Shares
Basic Shares Outstanding	1.5B	1.6B	1.2B	1.5B	1.5B
Diluted Shares Outstanding	1.5B	1.6B	1.2B	1.5B	1.5B
Profitability Metrics
EBITDA	—	210.3M	227.6M	114.3M	(1.4B)
D&A	—	193.5M	213.0M	240.9M	307.5M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026